Dandurand, Ann
Mayo Clinic
Otsuka Pharmaceutical Development & Commercialization, Inc. (United States)
Citations 1
Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial
Torres, Vicente E. , Chapman, Arlene B., Devuyst, Olivier , Gansevoort, Ron T. , Dandurand, Ann, Ouyang, John , Czerwiec, Frank S., Blais, Jaime D., Investigators, for the TEMPO 4:4 Trial, Perrone, Ronald D. , Investigators, for the TEMPO 4:4 Trial, Torres, Vicente E , Devuyst, Olivier; https://orcid.org/0000-0003-3744-4767
Nephrology Dialysis Transplantation | February 18, 2017 | Volume: 33 | Issue: 3 | Pages: 477-489
